RALEIGH, N.C.-- (BUSINESS WIRE) -- INC Research ^®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, today announced the appointment of Wayne Whittingham, as vice president, Regulatory Affairs and Strategic Drug Development. In this role, Whittingham is able to leverage his career experiences in federally regulated environments, technical regulatory expertise and project management skills to enhance and expand the capabilities of his team to better serve the overall global development needs of INC Research customers.

INC Research’s Regulatory Services team has a history of providing a comprehensive array of operational regulatory and medical writing support for regulatory submissions. The team works closely with the company’s growing Strategic Consulting Group (SCG) to offer customers specialized expertise in global regulatory issues. INC Research’s SCG, comprised of in-house MDs, PhDs and MBAs, are able to maximize the value of its customers’ intellectual property and portfolio content. Whittingham will provide leadership to both of these groups for a more synergistic approach to drug development.

“Wayne has the right mix of global regulatory affairs and hands-on clinical project management experience to help our customers navigate a highly regulated and increasingly complex drug development environment,” said Alistair Macdonald, general manager, Global Services at INC Research. “By including the role of regulatory affairs throughout each phase of our Trusted Process, Wayne and his team will continue to maximize the success of our customers’ global regulatory submissions.”

As a RAC Certified Regulatory Professional, Whittingham has more than 20 years direct experience in regulatory affairs and project management. Previously, he held senior management roles where he developed regulatory strategies and provided regulatory guidance to multidisciplinary projects with various pharmaceutical companies, including a venture capital firm that specialized in seed stage investments. He also held the international regulatory affairs role for a global pharmaceutical company and worked within the FDA for six years in CBER, CDER and CFSAN.

“I am thrilled to be able to apply my expertise to INC Research’s well-established team,” said Whittingham. “The intersection of regulatory affairs and strategic consulting helps INC Research provide highly experienced and comprehensive guidance to propel our customer’s R&D efforts.”

For more information on INC Research’s Regulatory Services and Strategic Consulting Group, visit www.incresearch.com

About INC Research^® Inc.

INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process^® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.